1Diabetes Comrol and Complications al Research Group(DCCT). The Effect of Intensive Treatment of Diabetes on the Development and Long-time complications in Insulin Dependem Diabetes Mellitus[J].N Engl J Med, 1993,329(14) :977- 986.
2UK Prospective Study(UKPDS)Group.Intensive Blood Glucose Control with Sulphonylureas or Insulin Compared with Type 2 Diabetes[J]. Lancet, 1998,352(9131) : 837- 853.
3Dailey G. New Strategies for Basal Insulin Treatment in Type 2 Diabetes Mellitus[J].Clin Ther,2004,26(6):889-901.
5Lepore M, Pampanelli S, Fanelli C, et a l. Pharmacokinetics and pharmacodynarnics of subcutaneous injection of long-acting human insulin analog glargine. NPH insulin. and uhralente human insulin and continuous subeutaneous infusion of ins[J]. Diabetes,2000,49(12):2142-2148.
二级参考文献15
1Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
2Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
3Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
4McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
5Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
6Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
7Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
8Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [ J ] .Diabetes Care,2000,23 : 1130-1136.
9Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose(FBG) and less symptomatic hypoglycemia with QD insulin glargine(Lautus) compare to bid NPH insulin in subjects with type 1 diabetes[J]. Diabetes,2001,50( Suppl 2) :116-117.
10Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine compared to bedtime NPH insulin in patients with type 2 diabetes [ J] . Diabetes, 2001,50(Suppl 2) : 112-113.
